Merck's Gardasil faces critical new hurdle

The FDA's approval of Gardasil as a vaccine to prevent cervical cancer faces a series of new critical hurdles. Chief among them is gaining the support of the Advisory Committee on Immunization Practice, which will be hugely influential in determining the states' attitude toward the new vaccine. Failure to gain ACIP's endorsement would slice into a market that may reach as high as $3 billion a year.

- here's the report [1] on Gardasil from TheStreet.com